Abstract: SA-PO0426
Tirzepatide in Mexican Patients with CKD: An Observational Study
Session Information
- CKM: Clinical - Epidemiology and Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Pérez Reyes, Sergio Victor, Hospital Regional Puebla ISSSTE, Puebla, Pue., Mexico
- Zenteno, Marely, Hospital Regional Puebla ISSSTE, Puebla, Pue., Mexico
- Perez Reyes, Alexis, Hospital Regional Puebla ISSSTE, Puebla, Pue., Mexico
- Lima, Brenda, Hospital Regional Puebla ISSSTE, Puebla, Pue., Mexico
Background
Tirzepatide has demonstrated efficacy in glycemic control and weight loss in patients with type 2 diabetes mellitus . However, there are limited studies evaluating the use of GLP-1 receptor agonists in patients with chronic kidney disease.
Methods
A total of 37 patients from a single medical center were included, of whom 20 were male and 17 female, with a mean age of 45 years. Eligible subjects were individuals with type 2 diabetes and stage III–IV chronic kidney disease who had received treatment with tirzepatide for more than 3 months, with glycated hemoglobin (HbA1c) ≥7.0% and an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m2, as well as proteinuria greater than 300 mg/dL. Patients were followed for 12 months.
Results
The primary outcome was the change in HbA1c, with an average reduction ranging from 1.1% to 2.0%. Weight loss exceeded 8% in all study subjects. A reduction in proteinuria levels was observed in all patients. Mean eGFR increased from 3.2 mL/min to 7 mL/min.
The adverse events reported, in order of frequency, were diarrhea, dyspepsia, and abdominal pain. None were severe. Only 3 patients discontinued the study due to financial reasons. No patient experienced worsening renal function during treatment with the medication.
Conclusion
Tirzepatide proved to be safe in advanced stages of chronic kidney disease and obesity. It did not increase the risk of hypoglycemia and may improve glomerular filtration rate in these patients.